Mark Bresnik

1.4k citations

25 papers · 884 indexed · 1 hit paper · h-index 11

Impact in

Infectious Diseases top 2%
- Antifungal resistance and susceptibility
Epidemiology top 5%
- Fungal Infections and Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Nail Diseases and Treatments

Papers in ⓘ

Infectious Diseases 11
- Antifungal resistance and susceptibility 11
- Parasitic Diseases Research and Treatment 2
Pulmonary and Respiratory Medicine 15
- Cystic Fibrosis Research Advances 13
- Inhalation and Respiratory Drug Delivery 12

Co-authors: Ramin Ebrahimi (4 shared papers)Johan Maertens (4 shared papers)Raoul Herbrecht (4 shared papers)Oliver A. Cornely (4 shared papers)Andrew J. Ullmann (2 shared papers)C. Rieger (1 shared paper)Dietmar Reichert (1 shared paper)Nicola Vianelli (1 shared paper)
Journals: Journal of Cystic Fibrosis (12 papers)Antimicrobial Agents and Chemotherapy (2 papers)Mycoses (2 papers)Open Forum Infectious Diseases (2 papers)Clinical Infectious Diseases (1 paper)
Partner nations: United States France United Kingdom

In The Last Decade

Mark Bresnik

22 papers receiving 866 citations

Hit Papers

align trajectories log scale

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial) 2007 · 486 citations

Peers

Countries citing papers authored by Mark Bresnik

Since Specialization

Citations

This map shows the geographic impact of Mark Bresnik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bresnik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bresnik more than expected).

Fields of papers citing papers by Mark Bresnik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bresnik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bresnik. The network helps show where Mark Bresnik may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Bresnik, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Bresnik Line = papers co-authored together Mark Bresnik links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial) Clinical Infectious Diseases ·Oliver A. Cornely, Johan Maertens, Mark Bresnik, Ramin Ebrahimi, Andrew J. Ullmann, Emilio Bouza, Claus Peter Heußel, O. Lortholary, C. Rieger, Angelika Boehme, M. Aoun, Heinz A. Horst, Anne Thiébaut, Markus Ruhnke, Dietmar Reichert, Nicola Vianelli, Stefan W. Krause, Eduardo Olavarría, Raoul Herbrecht, (unknown) Hit paper breakdown →	2007	486
2	Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial Journal of Cystic Fibrosis ·B.M. Assael, Tacjana Pressler, Diana Bilton, Michaël Fayon, Rainald Fischer, R. Chiron, M. Larosa, Christiane Knoop, Noel G. McElvaney, Sandra A. Lewis, Mark Bresnik, A. Bruce Montgomery, Christopher M. Oermann	2012	104
3	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease Mycoses ·Oliver A. Cornely, Johan Maertens, Mark Bresnik, Ramin Ebrahimi, E. Dellow, Raoul Herbrecht, J. Peter Donnelly	2010	47
4	Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study Journal of Cystic Fibrosis ·Harm A.W.M. Tiddens, K. De Boeck, John Clancy, Michaël Fayon, Arets H.G.M., Mark Bresnik, A. Derchak, Sarah Lewis, Christopher M. Oermann	2014	40
5	Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial Journal of Cystic Fibrosis ·D. Elizabeth Tullis, Jane L. Burns, George Retsch‐Bogart, Mark Bresnik, Noreen Henig, Sandra A. Lewis, John J. LiPuma	2013	39
6	Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis Journal of Cystic Fibrosis ·Patrick A. Flume, John P. Clancy, George Retsch‐Bogart, D. Elizabeth Tullis, Mark Bresnik, P.A. Derchak, Sandra A. Lewis, Bonnie W. Ramsey	2016	39
7	Liposomal Amphotericin B (L-AMB) as Initial Therapy for Invasive Filamentous Fungal Infections (IFFI): A Randomized, Prospective Trial of a High Loading Regimen vs. Standard Dosing (AmBiLoad Trial). Blood ·Oliver A. Cornely, Johan Maertens, Mark Bresnik, Raoul Herbrecht	2005	24
8	Liposomal amphotericin B (AmBisome^®) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis Mycoses ·Catherine Cordonnier, Mark Bresnik, Ramin Ebrahimi	2007	20
9	Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B Journal of Antimicrobial Chemotherapy ·Oliver A. Cornely, Johan Maertens, Mark Bresnik, Andrew J. Ullmann, Ramin Ebrahimi, Raoul Herbrecht	2009	14
10	A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever Journal of Medical Microbiology ·Michael Ellis, Roos Bernsen, Hussain Alizadeh, Jörgen Kristensen, Ulla Hedström, Lazaros Poughias, Mark Bresnik, Awad Alessa, David A. Stevens	2009	14
11	WS5.4 Aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (BURK) infection: final results from a randomized, placebo-controlled trial Journal of Cystic Fibrosis ·Elizabeth Tullis, J. Burns, G. Retsch-Bogart, Mark Bresnik, Noreen Henig, Steff Lewis, John J. LiPuma	2012	13
12	Pseudomonas aeruginosaSusceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation Antimicrobial Agents and Chemotherapy ·Claire Keating, Jonathan B. Zuckerman, Pradeep K. Singh, Matthew McKevitt, Oksana Gurtovaya, Mark Bresnik, Bruce C. Marshall, Lisa Saiman	2020	10
13	84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial Journal of Cystic Fibrosis ·Elizabeth Tullis, Jane L. Burns, G. Retsch-Bogart, Mark Bresnik, Steff Lewis, A. Bruce Montgomery, John J. LiPuma	2011	9
14	58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection Journal of Cystic Fibrosis ·J. Burns, John J. LiPuma, G. Retsch-Bogart, Mark Bresnik, Noreen Henig, Matt McKevitt, Sarah Lewis, Elizabeth Tullis	2012	8
15	107 In vitro susceptibility of Pseudomonas aeruginosa (PA) does not predict clinical response to aztreonam 75 mg powder and solvent for nebuliser solution (AZLI): a responder analysis in subjects with cystic fibrosis (CF) Journal of Cystic Fibrosis ·T. Pressler, B.M. Assael, R. Fischer, Mark Bresnik, Steff Lewis, Matt McKevitt, Anne Montgomery, Christopher M. Oermann	2011	5
16	86* Lung function improvement with aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in a single-arm extension of a randomized trial of inhaled antipseudomonal antibiotics in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa infection Journal of Cystic Fibrosis ·B.M. Assael, R. Chiron, R. Fischer, Mark Bresnik, Sarah Lewis, A. Bruce Montgomery, T. Pressler	2011	3
17	ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis Journal of Cystic Fibrosis ·Francis Gilchrist, S. Bui, Silvia Gärtner, Susanna A. McColley, Harm A.W.M. Tiddens, Gary Ruiz, Florian Stehling, Muhsen Al-ani, Oksana Gurtovaya, Mark Bresnik, Timothy R. Watkins, Biliana Frankovic, Marianne Skov	2023	2
18	ePS06.5 Post-hoc review of outcomes in patients switching from tobramycin for nebulization solution (TNS) to aztreonam lysine for inhalation (AZLI) Journal of Cystic Fibrosis ·Michaël Fayon, Christopher M. Oermann, T. Pressler, J. Wicklund, Jorunn Brekke, H. Liu, Mark Bresnik, B.M. Assael	2016	2
19	Lung Function Improvement In Cystic Fibrosis (CF) Subjects In Response To Treatment With Aztreonam For Inhalation Solution (AZLI) In A Single-Arm Extension Study After Multiple Courses Of Inhaled Antipseudomonal Antibiotics Mark Bresnik, B.M. Assael, R. Chiron, Rainald Fischer, Sandy Lewis, Allen B. Montgomery, Tacjana Pressler	2011	2
20	Antifungal therapy patterns, healthcare utilization, costs, and mortality in central nervous system and non-central nervous system disseminated coccidioidomycosis across the continuum-of-care Clinical Microbiology and Infection ·Fariba Donovan, Mark Bresnik, Belinda Lovelace, Lia Pizzicato, Vamshi Ruthwik Anupindi, Mitch DeKoven, Craig I Coleman	2025	1

About Mark Bresnik

Mark Bresnik is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine, Critical Care and Intensive Care Medicine, Epidemiology and Small Animals, having authored 25 papers that have together received 884 indexed citations. Recurring topics across this work include Cystic Fibrosis Research Advances (13 papers), Inhalation and Respiratory Drug Delivery (12 papers), Antifungal resistance and susceptibility (11 papers), Fungal Infections and Studies (10 papers), Pharmaceutical studies and practices (4 papers), Nail Diseases and Treatments (3 papers), Nosocomial Infections in ICU (2 papers) and Parasitic Diseases Research and Treatment (2 papers). The work is most often cited by research in Infectious Diseases (568 citations), Epidemiology (576 citations), Small Animals (98 citations), Pulmonary and Respiratory Medicine (300 citations) and Critical Care and Intensive Care Medicine (41 citations). Mark Bresnik has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Ramin Ebrahimi, Johan Maertens, Raoul Herbrecht, Oliver A. Cornely, Andrew J. Ullmann, C. Rieger, Dietmar Reichert, Nicola Vianelli, Anne Thiébaut and Eduardo Olavarría. Their work appears in journals such as Journal of Cystic Fibrosis, Antimicrobial Agents and Chemotherapy, Mycoses, Open Forum Infectious Diseases and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact